Metformin XR + Saxagliptin + Saxagliptin-Metformin XR
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Ovary Syndrome
Conditions
Polycystic Ovary Syndrome, Disorder of Glucose Regulation
Trial Timeline
Mar 1, 2014 → Oct 1, 2016
NCT ID
NCT02022007About Metformin XR + Saxagliptin + Saxagliptin-Metformin XR
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR is a phase 3 stage product being developed by AstraZeneca for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02022007. Target conditions include Polycystic Ovary Syndrome, Disorder of Glucose Regulation.
What happened to similar drugs?
3 of 13 similar drugs in Polycystic Ovary Syndrome were approved
Approved (3) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02022007 | Phase 3 | Completed |
Competing Products
20 competing products in Polycystic Ovary Syndrome